Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies

Duhoux, François;Ameye, Geneviève;Lambot, Virginie;Herens, Christian;Poirel, Hélène;et.al.
(2011) PLoS One — Vol. 6, n° 10, p. e26311 [1-9] (2011)

Files

pdfdocument.pdf
  • Open Access
  • Adobe PDF
  • 906.8 KB

Details

Authors
  • Author
  • Ameye, GenevièveUCLouvain
    Author
  • Lambot, VirginieUCLouvain
    Author
  • Herens, ChristianCHU de Liège
    Author
  • Michaux, LucienneUCLouvain
    Author
  • Libouton, Jeanne-MarieUCLouvain
    Author
  • Author
  • Author
  • Poirel, HélèneUCLouvain
    Author
  • et. al.
Show more
Abstract
Fluorescence in situ hybridization was performed to characterize 81 cases of myeloid and lymphoid malignancies with cytogenetic 1p36 alterations not affecting the PRDM16 locus. In total, three subgroups were identified: balanced translocations (N = 27) and telomeric rearrangements (N = 15), both mainly observed in myeloid disorders; and unbalanced non-telomeric rearrangements (N = 39), mainly observed in lymphoid proliferations and frequently associated with a highly complex karyotype. The 1p36 rearrangement was isolated in 12 cases, mainly myeloid disorders. The breakpoints on 1p36 were more widely distributed than previously reported, but with identifiable rare breakpoint cluster regions, such as the TP73 locus. We also found novel partner loci on 1p36 for the known multi-partner genes HMGA2 and RUNX1. We precised the common terminal 1p36 deletion, which has been suggested to have an adverse prognosis, in B-cell lymphomas [follicular lymphomas and diffuse large B-cell lymphomas with t(14;18)(q32;q21) as well as follicular lymphomas without t(14;18)]. Intrachromosomal telomeric repetitive sequences were detected in at least half the cases of telomeric rearrangements. It is unclear how the latter rearrangements occurred and whether they represent oncogenic events or result from chromosomal instability during oncogenesis.
Affiliations
  • CHU de LiègeCenter for Human Genetics
  • CHU de NiceCenter for Human Genetics
  • KULeuvenCenter for Human Genetics
  • CHU de LilleCenter for Human Genetics
  • CHU de MontpellierCenter for Human Genetics
  • Groupe Hospitalier Pitié-SalpétrièreCenter for Human Genetics
  • Hôpital Purpan, ToulouseCenter for Human Genetics
  • CHU de BordeauxCenter for Human Genetics
  • UZ GhentCenter for Human Genetics
  • IPGCenter for Human Genetics
  • CHU de NantesCenter for Human Genetics
  • CHU de DijonCenter for Human Genetics
  • Centre Hospitalier Lyon SudCenter for Human Genetics
  • Institut Paoli-CalmettesCenter for Human Genetics
  • CHU Hôpital Nord, Saint-EtienneCenter for Human Genetics
  • Centre Hospitalier de VersaillesCenter for Human Genetics

Citations

Duhoux, F., Ameye, G., Lambot, V., Herens, C., Labis, E., Terré, C., Nadal, N., Laibe, S., Mozziconacci, M.-J., Raynaud, S., Wlodarska, I., Michaux, L., Roche-Lestienne, C., Libouton, J.-M., Decottignies, A., Taviaux, S., Chapiro, E., Nguyen Khac, F., Struski, S., et al. (2011). Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One, 6(10), e26311 [1-9]. https://hdl.handle.net/2078.5/92990 (Original work published 2011)